Table 2. IMbrave050 safety summary.
Events | Atezo + bev (n=332) | Active surveillance (n=330) |
---|---|---|
Treatment duration, median, months | Atezo: 11.1, Bev: 11.0 | NA |
Treatment AE (%) | 88.3 | NA |
Grade 3/4 AE (%) | 41.0 | 13.3 |
Serious AE (%) | 24.1 | 10.3 |
Grade 5 AE (%) | 1.8 | 0.3 |
AE leading to dose interruption of any study treatment (%) | 46.7 | NA |
AE leading to withdrawal from any study treatment (%) | 19.0 | NA |
AE, adverse event, NA, not applicable.